PubMed · 8458710
Immunomodulation with soluble IFN-gamma receptor: preliminary study.
Abstract
Several in vivo experiments support the hypothesis that an IFN-gamma antagonist may have therapeutic applications in autoimmune diseases, hypersensitivities, and alloreactions. IFN-gamma exerts its biological activity through the binding to a single-chain cell surface receptor. The protein that corresponds to the external domain of mouse IFN-gamma receptor was expressed in insect cells infected with recombinant baculovirus; this protein was characterized and used in vivo as a prototype of the IFN-gamma antagonist. This protein does not show any strong antigenicity after in vivo injection in mice. Despite a blood half-life of only 1-3 hr as demonstrated in pharmacokinetic experiments, the mouse soluble IFN-gamma R was able to modify the onset of acute GVHD (alloreaction) and chronic GVHD (lupuslike disease).
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
L Ozmen, M Fountoulakis, R Gentz, G Garotta. 1993. Immunomodulation with soluble IFN-gamma receptor: preliminary study.. https://doi.org/10.1016/b978-0-12-364935-5.50014-6
Cite the original work for its findings. Save a collection to share your selection of sources.